Reshma Esmail

Improvement in Cardiovascular Risk Markers with Glimepiride in Non Obese Subjects with Pre Diabetes: Similar to Obese Cohort Treated with Metformin

Reshma Esmail & Udaya Manohar Kabadi · Journal of Advances in Medicine and Medical Research · 2016

Background: We recently documented better efficacy of glimepiride in non obese subjects for delaying progression from Pre diabetes to type 2 diabetes as compared to metformin in obese subjects over duration of 5-9 years (mean, 7.2±0.2). Moreover, no deaths or adverse cardiovascul...